Skip to main content
. 2015 Sep 3;42(9):1082–1092. doi: 10.1111/apt.13387

Figure 2.

Figure 2

Proportion of patients randomised to adalimumab 160/80 mg with (a) rectal bleeding and (b) stool frequency subscores of 0, 1, 2 or 3 per each endoscopy subscore value at Week 8. ES, endoscopy subscore; RBS, rectal bleeding subscore; SFS, stool frequency subscore.